Seeking Alpha·Sep 15, 2026
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptVeracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Veracyte's accelerating revenue growth (15.5% YoY in 2026Q2) and expanding gross margins (72.6%) demonstrate strong operational leverage, with operating income swinging from -$5.3M to $22.7M year-over-year. The company's capital-light model (CapEx/Revenue of 1...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.54+31.6% vs $0.41 | $150M+4.0% vs $145M |
Q2 2026 May 5, 2026 | $0.52+52.9% vs $0.34 | $139M+6.7% vs $130M |
Q1 2026 Feb 25, 2026 | $0.53+29.8% vs $0.41 | $141M+3.6% vs $136M |
Q4 2025 Nov 4, 2025 | $0.51+59.4% vs $0.32 | $132M+5.5% vs $125M |
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick amid a challenging price performance over the past month, whic
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
Benchmark VCYT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Veracyte, Inc. (VCYT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $43.82 | $3.5B | 53.44 | 16.01% | 12.83% | 5.34% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $390.79 | $55.97B | -257.10 | 35.9% | -7.11% | -11.73% | — | |
| $54.31 | $2.81B | -135.78 | 13.79% | 24.23% | 32.81% | — | |
| $62.87 | $642.03M | 17.46 | 20.23% | 27.3% | 13.02% | — | |
| $34.10 | $1.38B | 28.66 | 27.37% | 6.57% | 28.67% | — |
Veracyte, Inc. (VCYT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Veracyte, Inc. (VCYT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 11, 2026·SEC
May 5, 2026·SEC
Get notified when VCYT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Veracyte, Inc. (VCYT) stock FAQ — growth, dividends, profitability & financials explained
Veracyte, Inc. (VCYT) reported $561.9M in revenue for fiscal year 2025. This represents a 21144% increase from $2.6M in 2011.
Veracyte, Inc. (VCYT) grew revenue by 16.0% over the past year. This is strong growth.
Yes, Veracyte, Inc. (VCYT) is profitable, generating $114.5M in net income for fiscal year 2025 (12.8% net margin).
Veracyte, Inc. (VCYT) has a return on equity (ROE) of 5.3%. This is below average, suggesting room for improvement.
Veracyte, Inc. (VCYT) generated $165.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
